If investigators engaged in the field of islet xenotransplantation are careful to engage early enough in the “quality by design approach” advocated by Piemonti [17], islet xenotransplantation might find itself having an edge in the pursuit for an “infinite” source of insulin-producing tissue, available to all patients with T1DM without the need for lifelong immunosuppression. Here, INS is linked to type 1 diabetes mellitus.